dm+d

111165009

Articles

Safety in lactation: Drugs for chronic bowel disorders

21 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Aminosalicylates for chronic bowel disorders Mesalazine…

Safety in Lactation: Systemic preparations for eczema and psoriasis

7 January 2019Drugs used orally or parenterally for severe eczema and psoriasis have a varied pharmacology, mainly either modifying the immune response to the disease or modifying…
Search Articles

Medicine Compliance Aid Stability

ImuranAspen

Aspen
Imuran
Tablets f/c 25mg, 50mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light. Airtight container
25 September 2015

Lactation Safety Information

In transplantation

In transplantation
See summary
Moderate level of published evidence of use in breastfeeding
Small amounts of active metabolite, 6-mercaptopurine, in breast milk
If high dose used, monitor infant blood counts
24 September 2020

For rheumatoid arthritis

For rheumatoid arthritis
See summary
Moderate level of published evidence of use in breastfeeding
Small amounts of active metabolite, 6-mercaptopurine, in breast milk
If high dose used, monitor infant blood counts
24 September 2020

For eczema

For eczema
Topical eczema preparation / corticosteroid if appropriate
Unlicensed indication in the UK
Moderate level of published evidence of use in breastfeeding
Small amounts of active metabolite, 6-mercaptopurine, in breast milk
Monitor for signs of infection and immunosuppression, and, if high dose used, infant blood counts
24 September 2020

For inflammatory bowel disease

For inflammatory bowel disease
See summary
Moderate level of published evidence of use in breastfeeding
Small amounts of active metabolite, 6-mercaptopurine, in breast milk
If high dose used, monitor infant blood counts
24 September 2020

New Medicines

Jayempi Autoimmune disorders and inflammatory conditions - oral suspension formulation

Information

Jayempi
New formulation
Nova Laboratories
Not Known

Development and Regulatory status

Approved (Licensed)
None
None
Jul 21Approved by the MHRA for use in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Also as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. And in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic - medicinal products – DMARDs), auto-immune hepatitis, systemic lupus erythematosus, dermatomyositis, polyarteritis nodosa, pemphigus vulgaris and bullous pemphigoid, Behçet´s disease, refractory auto-immune haemolytic anaemia, caused by warm IgG antibodies, and chronic refractory idiopathic thrombocytopenic purpura. Also for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn´s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. And in adults with relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. And in the treatment of generalised myasthenia gravis [1].

Category

An inactive pro-drug of 6-mercaptopurine (6-MP), which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides (TGNs) for immunosuppression
Various as multiple indications
Autoimmune disorders and inflammatory conditions - oral suspension formulation
Oral